Cite
MLA Citation
H. Rugo et al.. “HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin.” European journal of cancer, vol. 72, n.d., pp. S41–. http://access.bl.uk/ark:/81055/vdc_100041522076.0x00002a